Treatment and Management of Neuromuscular Channelopathies

Lydia Sharp, Jaya R. Trivedi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Neuromuscular channelopathies are heterogeneous disorders with marked phenotypic and genotypic variability. These include non-dystrophic myotonia (NDM), periodic paralysis (PP), and congenital myasthenic syndrome (CMS). Their diverse clinical manifestations remain a challenge in diagnosis and management to this date. These disorders impact quality of life and cause lifelong disabling symptoms. Treatment options are few and not FDA-approved. This is largely due to a paucity of large, randomized clinical trials in these rare diseases. Challenges of conducting such trials include the rarity of these disorders and the genetic heterogeneity. Physicians rely on off-label use of drugs to treat muscle channelopathies to reduce morbidity and improve quality of life. Besides pharmacological treatment, dietary modifications, lifestyle changes, awareness of triggers, and genetic counseling also play an important role in long-term disease management. This article reviews the current management strategies for neuromuscular channelopathies.

Original languageEnglish (US)
JournalCurrent Treatment Options in Neurology
Volume16
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

Channelopathies
Congenital Myasthenic Syndromes
Quality of Life
Myotonia
Off-Label Use
Diet Therapy
Genetic Heterogeneity
Genetic Counseling
Disease Management
Rare Diseases
Paralysis
Life Style
Therapeutics
Randomized Controlled Trials
Pharmacology
Morbidity
Physicians
Muscles
Pharmaceutical Preparations

Keywords

  • Acetazolamide
  • Andersen-Tawil syndrome
  • Channelopathies
  • Congenital myasthenic syndrome
  • Fluoxetine
  • Heterogeneous
  • Hyperkalemia
  • Hypokalemia
  • Mexiletine
  • Non-dystrophic myotonia
  • Periodic paralysis
  • Potassium
  • Quinidine

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Treatment and Management of Neuromuscular Channelopathies. / Sharp, Lydia; Trivedi, Jaya R.

In: Current Treatment Options in Neurology, Vol. 16, No. 10, 01.10.2014.

Research output: Contribution to journalArticle

@article{3c72c4c3c40b43a1a5fbaca7098c51c3,
title = "Treatment and Management of Neuromuscular Channelopathies",
abstract = "Neuromuscular channelopathies are heterogeneous disorders with marked phenotypic and genotypic variability. These include non-dystrophic myotonia (NDM), periodic paralysis (PP), and congenital myasthenic syndrome (CMS). Their diverse clinical manifestations remain a challenge in diagnosis and management to this date. These disorders impact quality of life and cause lifelong disabling symptoms. Treatment options are few and not FDA-approved. This is largely due to a paucity of large, randomized clinical trials in these rare diseases. Challenges of conducting such trials include the rarity of these disorders and the genetic heterogeneity. Physicians rely on off-label use of drugs to treat muscle channelopathies to reduce morbidity and improve quality of life. Besides pharmacological treatment, dietary modifications, lifestyle changes, awareness of triggers, and genetic counseling also play an important role in long-term disease management. This article reviews the current management strategies for neuromuscular channelopathies.",
keywords = "Acetazolamide, Andersen-Tawil syndrome, Channelopathies, Congenital myasthenic syndrome, Fluoxetine, Heterogeneous, Hyperkalemia, Hypokalemia, Mexiletine, Non-dystrophic myotonia, Periodic paralysis, Potassium, Quinidine",
author = "Lydia Sharp and Trivedi, {Jaya R.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1007/s11940-014-0313-6",
language = "English (US)",
volume = "16",
journal = "Current Treatment Options in Neurology",
issn = "1092-8480",
publisher = "Current Science, Inc.",
number = "10",

}

TY - JOUR

T1 - Treatment and Management of Neuromuscular Channelopathies

AU - Sharp, Lydia

AU - Trivedi, Jaya R.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Neuromuscular channelopathies are heterogeneous disorders with marked phenotypic and genotypic variability. These include non-dystrophic myotonia (NDM), periodic paralysis (PP), and congenital myasthenic syndrome (CMS). Their diverse clinical manifestations remain a challenge in diagnosis and management to this date. These disorders impact quality of life and cause lifelong disabling symptoms. Treatment options are few and not FDA-approved. This is largely due to a paucity of large, randomized clinical trials in these rare diseases. Challenges of conducting such trials include the rarity of these disorders and the genetic heterogeneity. Physicians rely on off-label use of drugs to treat muscle channelopathies to reduce morbidity and improve quality of life. Besides pharmacological treatment, dietary modifications, lifestyle changes, awareness of triggers, and genetic counseling also play an important role in long-term disease management. This article reviews the current management strategies for neuromuscular channelopathies.

AB - Neuromuscular channelopathies are heterogeneous disorders with marked phenotypic and genotypic variability. These include non-dystrophic myotonia (NDM), periodic paralysis (PP), and congenital myasthenic syndrome (CMS). Their diverse clinical manifestations remain a challenge in diagnosis and management to this date. These disorders impact quality of life and cause lifelong disabling symptoms. Treatment options are few and not FDA-approved. This is largely due to a paucity of large, randomized clinical trials in these rare diseases. Challenges of conducting such trials include the rarity of these disorders and the genetic heterogeneity. Physicians rely on off-label use of drugs to treat muscle channelopathies to reduce morbidity and improve quality of life. Besides pharmacological treatment, dietary modifications, lifestyle changes, awareness of triggers, and genetic counseling also play an important role in long-term disease management. This article reviews the current management strategies for neuromuscular channelopathies.

KW - Acetazolamide

KW - Andersen-Tawil syndrome

KW - Channelopathies

KW - Congenital myasthenic syndrome

KW - Fluoxetine

KW - Heterogeneous

KW - Hyperkalemia

KW - Hypokalemia

KW - Mexiletine

KW - Non-dystrophic myotonia

KW - Periodic paralysis

KW - Potassium

KW - Quinidine

UR - http://www.scopus.com/inward/record.url?scp=84939877261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939877261&partnerID=8YFLogxK

U2 - 10.1007/s11940-014-0313-6

DO - 10.1007/s11940-014-0313-6

M3 - Article

C2 - 25118992

AN - SCOPUS:84939877261

VL - 16

JO - Current Treatment Options in Neurology

JF - Current Treatment Options in Neurology

SN - 1092-8480

IS - 10

ER -